Skip to main content
Top
Published in: Immunologic Research 1/2017

01-02-2017 | Mechanism in Autoimmunity

Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events

Authors: Arpad Zsigmond Barabas, Chad Douglas Cole, Richard Milton Graeff, Rene Lafreniere, Donald Mackay Weir

Published in: Immunologic Research | Issue 1/2017

Login to get access

Abstract

Autoimmunity has both beneficial and harmful aspects. Beneficial aspects include: (1) removal of released intracytoplasmic antigens (ags) (cells at the end of their life span or damaged by outside agents) by specific nonpathogenic IgM autoantibodies and mononuclear cells and (2) recognition and elimination of cancerous cells. In contrast, harmful aspects include: (1) mounting a pathogenic autoimmune response against a tissue-derived ag, a ‘modified self,’ resulting in autoimmune disease and (2) inability to recognize and eliminate a cancerous clone. The immune system continuously faces internal and external influences; however, even when it is compromised or overwhelmed, it will still endeavor to regain and maintain tolerance to self. To promote this, we developed a ‘modified vaccination technique’ (MVT) (described as the third vaccination method after active and passive immunizations). It has two components: purified exogenous/endogenous ag (i.e., target ag) and a high-titer-specific antibody (ab) against the target ag made into an immune complex (IC) with predetermined immune-inducing components. The MVT works by ab information transfer (production of same class of immunoglobulin with the same specificity against the target ag that is present in the vaccine), thereby re-establishing tolerance to self (caused by exogenous/endogenous ags) following repeated administration of appropriate ICs. This vaccination technique can be used both prophylactically and therapeutically, and it mimics the immune system’s natural abilities to respond to corrective information specifically, rapidly, safely and with minimal side effects and makes this approach a novel solution for many disorders that are difficult or impossible to cure or manage.
Literature
1.
go back to reference Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol. 1966;1(4):433–42.PubMedPubMedCentral Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol. 1966;1(4):433–42.PubMedPubMedCentral
2.
go back to reference Weir DM, Elson CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum. 1969;12(3):254–60.CrossRefPubMed Weir DM, Elson CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum. 1969;12(3):254–60.CrossRefPubMed
4.
go back to reference Weir DM. The immune response after tissue injury. Pathol Eur. 1966;1(1):108–18.PubMed Weir DM. The immune response after tissue injury. Pathol Eur. 1966;1(1):108–18.PubMed
5.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol. 2003;84(6):245–58.CrossRefPubMedPubMedCentral Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol. 2003;84(6):245–58.CrossRefPubMedPubMedCentral
6.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol. 2004;85(5):277–85.CrossRefPubMedPubMedCentral Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol. 2004;85(5):277–85.CrossRefPubMedPubMedCentral
7.
8.
go back to reference Soldan SS, Jacobson S. Infection and multiple sclerosis. In: Shoenfeld Y, Rosenzweig LJ, editors. Infection and autoimmunity. Amsterdam: Elsevier; 2004. p. 559–82.CrossRef Soldan SS, Jacobson S. Infection and multiple sclerosis. In: Shoenfeld Y, Rosenzweig LJ, editors. Infection and autoimmunity. Amsterdam: Elsevier; 2004. p. 559–82.CrossRef
9.
go back to reference Totoritis MC, Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med. 1985;78(3):149–61.CrossRefPubMed Totoritis MC, Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med. 1985;78(3):149–61.CrossRefPubMed
11.
go back to reference Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin N Am. 1994;20(1):61–86. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin N Am. 1994;20(1):61–86.
12.
go back to reference Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA. 2000;97(3):1184–9.CrossRefPubMedPubMedCentral Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA. 2000;97(3):1184–9.CrossRefPubMedPubMedCentral
13.
go back to reference Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol. 2005;35(1):252–60.CrossRefPubMed Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol. 2005;35(1):252–60.CrossRefPubMed
14.
go back to reference Wermeling F, Karlsson MC, McGaha TL. An anatomical view on macrophages in tolerance. Autoimmun Rev. 2009;9(1):49–52.CrossRefPubMed Wermeling F, Karlsson MC, McGaha TL. An anatomical view on macrophages in tolerance. Autoimmun Rev. 2009;9(1):49–52.CrossRefPubMed
15.
go back to reference Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 2005;26(4):425–32.CrossRefPubMed Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 2005;26(4):425–32.CrossRefPubMed
16.
go back to reference Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005;38(4):259–64.CrossRefPubMed Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005;38(4):259–64.CrossRefPubMed
17.
go back to reference Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today. 1991;12(5):154–9.PubMed Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today. 1991;12(5):154–9.PubMed
18.
go back to reference Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity. 2004;37(2):95–102.CrossRefPubMed Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity. 2004;37(2):95–102.CrossRefPubMed
19.
20.
go back to reference Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17(3):791–5.CrossRefPubMed Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17(3):791–5.CrossRefPubMed
21.
go back to reference Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5(8):433–41.CrossRefPubMed Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5(8):433–41.CrossRefPubMed
22.
go back to reference Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100.
23.
go back to reference Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005;4(8):526–31.CrossRefPubMed Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005;4(8):526–31.CrossRefPubMed
25.
go back to reference Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83.CrossRefPubMed Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83.CrossRefPubMed
26.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol. 2004;85(6):321–34.CrossRefPubMedPubMedCentral Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol. 2004;85(6):321–34.CrossRefPubMedPubMedCentral
27.
go back to reference Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev. 2005;4(8):565–70.CrossRefPubMed Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev. 2005;4(8):565–70.CrossRefPubMed
28.
go back to reference Barabas AZ, Cole CD, Lafreniere R, Weir DM. Regaining tolerance to a self-antigen by the modified vaccination technique. Clin Rev Allergy Immunol. 2013;45(2):193–201.CrossRefPubMed Barabas AZ, Cole CD, Lafreniere R, Weir DM. Regaining tolerance to a self-antigen by the modified vaccination technique. Clin Rev Allergy Immunol. 2013;45(2):193–201.CrossRefPubMed
29.
go back to reference Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun. 2010;34(3):J287–99.CrossRefPubMed Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun. 2010;34(3):J287–99.CrossRefPubMed
30.
go back to reference Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J. 2007;6(4):12–8.CrossRef Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J. 2007;6(4):12–8.CrossRef
31.
go back to reference Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol. 2010;71(3):125–33.CrossRefPubMed Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol. 2010;71(3):125–33.CrossRefPubMed
32.
go back to reference Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005;435(7042):612–9.CrossRefPubMed Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005;435(7042):612–9.CrossRefPubMed
33.
go back to reference Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25(6):862–75.CrossRefPubMed Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25(6):862–75.CrossRefPubMed
34.
go back to reference Pani A. Standard immunosuppressive therapy of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):848–53.CrossRefPubMed Pani A. Standard immunosuppressive therapy of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):848–53.CrossRefPubMed
35.
go back to reference Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44(3):385–401.CrossRefPubMed Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44(3):385–401.CrossRefPubMed
36.
go back to reference Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R. Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit. 2007;13(5):BR119–24.PubMed Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R. Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit. 2007;13(5):BR119–24.PubMed
37.
go back to reference Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, et al. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci. 2009;14:3892–8.CrossRef Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, et al. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci. 2009;14:3892–8.CrossRef
38.
go back to reference Barabas AZ, Cole CD, Sensen M, Lafreniere R. Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol. 2012;93(1):11–7.CrossRefPubMedPubMedCentral Barabas AZ, Cole CD, Sensen M, Lafreniere R. Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol. 2012;93(1):11–7.CrossRefPubMedPubMedCentral
39.
go back to reference Mackay IR. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev. 2010;9(5):A251–8.CrossRefPubMed Mackay IR. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev. 2010;9(5):A251–8.CrossRefPubMed
41.
go back to reference Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol. 2009;70(6):516–25.CrossRefPubMed Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol. 2009;70(6):516–25.CrossRefPubMed
42.
go back to reference Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev. 2009;8(7):552–7.CrossRefPubMed Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev. 2009;8(7):552–7.CrossRefPubMed
43.
44.
go back to reference Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med. 1959;100:660–4.CrossRefPubMed Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med. 1959;100:660–4.CrossRefPubMed
45.
go back to reference Barabas AZ, Cole CD, Barabas AD, Cowan JM, Yoon CS, Waisman DM, et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol. 2004;85(4):201–12.CrossRefPubMedPubMedCentral Barabas AZ, Cole CD, Barabas AD, Cowan JM, Yoon CS, Waisman DM, et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol. 2004;85(4):201–12.CrossRefPubMedPubMedCentral
46.
go back to reference Barabas AZ, Cole CD, Lafreniere R, Weir DM. Implicated autoantibodies in a kidney disease. In: Jenkins GE, Hall JI, editors. Autoantibodies: detection, pathogenicity and health implications. Hauppauge: Nova Science Publishers, Inc; 2012. p. 1–36. Barabas AZ, Cole CD, Lafreniere R, Weir DM. Implicated autoantibodies in a kidney disease. In: Jenkins GE, Hall JI, editors. Autoantibodies: detection, pathogenicity and health implications. Hauppauge: Nova Science Publishers, Inc; 2012. p. 1–36.
47.
go back to reference Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S. Formation of immune deposits and disease. Lab Invest. 1986;55(5):510–20.PubMed Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S. Formation of immune deposits and disease. Lab Invest. 1986;55(5):510–20.PubMed
48.
49.
go back to reference Ronco P, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol. 2006;17(7):1772–4.CrossRefPubMed Ronco P, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol. 2006;17(7):1772–4.CrossRefPubMed
50.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int. 2006;56(4):181–90.CrossRefPubMed Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int. 2006;56(4):181–90.CrossRefPubMed
51.
go back to reference Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010;16(7):799–803.CrossRefPubMedPubMedCentral Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010;16(7):799–803.CrossRefPubMedPubMedCentral
52.
go back to reference von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31.CrossRef von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31.CrossRef
53.
go back to reference Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.CrossRefPubMed Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.CrossRefPubMed
54.
go back to reference Kabe KL, Kolesar JM. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm. 2006;63(6):527–33.CrossRefPubMed Kabe KL, Kolesar JM. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm. 2006;63(6):527–33.CrossRefPubMed
55.
go back to reference Munshi C, Aarhus R, Graeff R, Walseth TF, Levitt D, Lee HC. Identification of the enzymatic active site of CD38 by site-directed mutagenesis. J Biol Chem. 2000;275(28):21566–71.CrossRefPubMed Munshi C, Aarhus R, Graeff R, Walseth TF, Levitt D, Lee HC. Identification of the enzymatic active site of CD38 by site-directed mutagenesis. J Biol Chem. 2000;275(28):21566–71.CrossRefPubMed
56.
go back to reference Munshi CB, Fryxell KB, Lee HC, Branton WD. Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol. 1997;280:318–30.CrossRefPubMed Munshi CB, Fryxell KB, Lee HC, Branton WD. Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol. 1997;280:318–30.CrossRefPubMed
Metadata
Title
Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events
Authors
Arpad Zsigmond Barabas
Chad Douglas Cole
Richard Milton Graeff
Rene Lafreniere
Donald Mackay Weir
Publication date
01-02-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8842-6

Other articles of this Issue 1/2017

Immunologic Research 1/2017 Go to the issue